Viemed’s growth engines fire as vent, sleep patient counts climb

LAFAYETTE, La. – Viemed Healthcare reported net revenues of $78.1 million for the second quarter, a 23.9% increase compared to the prior-year quarter and a company record.

The company also reported:

• Net income was $2.8 million, or $0.07 per diluted share
• Adjusted EBITDA was $13.7 million, a 4% decrease. The prior year period included a $1.0 million non-recurring gain on disposal of property and equipment related to the ventilator return program, which benefited net income and concluded during 2025
• Net cash provided by operating activities was $15.9 million

"The strength of these results reflects the durable and increasingly diversified company we have built,” said Casey Hoyt, CEO. “Viemed has multiple growth engines, strong cash generation, a solid balance sheet, and the financial flexibility to continue investing in our people, technology, and patient care capabilities. We are making those investments deliberately to support the patient growth already entering the platform, and we enter the second half of 2026 confident in Viemed's ability to deliver consistent and increasingly predictable growth."

Viemed ended the second quarter with a record 12,635 ventilator patients, a 4% increase compared to the prior-year quarter.

The company increased its PAP therapy patient count to 37,825 as of June 30, 2026, a 44% increase compared to the prior-year quarter and increased its sleep resupply patient count by 46.7%.

Viemed has updated its full-year guidance to:

• Net revenue is now expected to be in the range of $314 million to $320 million, compared with the previous range of $312 million to $320 million
• Adjusted EBITDA is now expected to range from $64 million to $68 million, compared with the previous range of $65 million to $69 million
• Net capital expenditures are now expected to range from 8.5% to 10.0% of net revenue, compared with the previous range of 9.0% to 10.5%

Related: Viemed juggles diversified portfolio.